- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The PAN Foundation Opens New Waldenstrom Macroglobulinemia Patient Assistance Fund
The Patient Access Network (PAN) Foundation today opened a new patient assistance program for people living with Waldenstrom macroglobulinemia, a rare type of blood cancer that originates in the lymphatic system and is characterized by an excess of abnormal white blood cells and proteins called immunoglobulins.
The Patient Access Network (PAN) Foundation today opened a new patient assistance program for people living with Waldenstrom macroglobulinemia. Waldenstrom macroglobulinemia is a rare type of blood cancer that originates in the lymphatic system and is characterized by an excess of abnormal white blood cells and proteins called immunoglobulins.
The American Cancer Society estimates that 1500 people are diagnosed with Waldenstrom macroglobulinemia each year in the United States. Qualifying patients are eligible to receive grants from PAN to pay for the deductibles, co-pays and coinsurance costs associated with their treatment for Waldenstrom macroglobulinemia.
“The financial impact of a cancer diagnosis can be life-changing for patients and their families,” said PAN President and Chief Executive Officer Daniel Klein. “We know that people living with cancer are often forced to delay or forgo treatment because they cannot afford their out-of-pocket costs. We’re proud to provide financial assistance to patients living with Waldenstrom macroglobulinemia so that they can access the treatments they need and avoid having to make difficult decisions about their health.”
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
